AstraZeneca PLC has come on board as a new big pharma partner to help the University of Oxford realise its hugely ambitious plans to have its COVID-19 vaccine ready by September.
The UK-headquartered firm announced on 30 April that it had accepted the challenge to lead late-stage development of the adenovirus-based...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
